A practical reference on GHS-R1a: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
==== Gram-negative bacteria ==== Outer membrane vesicles (OMVs), that can transfer DNA between bacterial cells, are produced by metabolically active bacterial cells, and the OMVs are not the result of cell lysis or cell death. Pathogenic strains can produce about 10-25 times more vesicles than a nonpathogenic strain making this highly relevant to carbapenem resistance transfer. OMVs protect plasmids from being digested extracellularly by nucleases that may be found in the environment, thus favoring horizontal gene transfer.
== Evolutionary diversity == Most mammals have MHC variants similar to those of humans, who bear great allelic diversity, especially among the nine classical genes—seemingly due largely to gene duplication—though human MHC regions have many pseudogenes. The most diverse loci, namely HLA-A, HLA-B, and HLA-C, have roughly 6000, 7200, and 5800 known alleles, respectively. Many HLA alleles are ancient, sometimes of closer homology to a chimpanzee MHC alleles than to some other human alleles of the same gene. MHC allelic diversity has challenged evolutionary biologists for explanation. Most posit balancing selection (see polymorphism (biology)), which is any natural selection process whereby no single allele is absolutely most fit, such as frequency-dependent selection and heterozygote advantage. Pathogenic coevolution, as a type of balancing selection, posits that common alleles are under greatest pathogenic pressure, driving positive selection of uncommon alleles—moving targets, so to say, for pathogens. As pathogenic pressure on the previously common alleles decreases, their frequency in the population stabilizes, and remain circulating in a large population. Genetic drift is also a major driving force in some species. It is possible that the combined effects of some or all of these factors cause the genetic diversity. Beyond allelic polymorphism, the degree of evolutionary divergence between MHC alleles within individuals also influences immune function.
The breasts are principally composed of adipose, glandular, and connective tissues. Because these tissues have hormone receptors, their sizes and volumes fluctuate according to the hormonal changes particular to thelarche (sprouting of breasts), menstruation (egg production), pregnancy (reproduction), lactation (feeding of offspring), and menopause (end of menstruation).
A 1960 Polish paper by Biniecki and Krajewski describing the synthesis of MDMA as an intermediate was the first published scientific paper on the substance. The first administration of MDMA to humans is unknown. MDA appeared as a recreational drug in the mid-1960s. MDMA may have been in non-medical use in the western United States in 1968. An August 1970 report at a meeting of crime laboratory chemists indicates MDMA was being used recreationally in the Chicago area by 1970. MDMA likely emerged as a substitute for MDA, a drug at the time popular among users of psychedelics which was made a Schedule 1 controlled substance in the United States in 1970.
Sources: en.wikipedia.org
=== Key market drivers === Consumer empowerment: Growing interest in preventive healthcare and personal health optimization has driven demand for accessible testing options. Technological advances: Innovations in sample collection (including at-home blood collection with minimal blood volume requirements) and point-of-care testing have made DTC testing more convenient and accessible. Chronic disease prevalence: Rising rates of diabetes (affecting 37.3 million Americans according to the CDC), cardiovascular disease, and other chronic conditions have increased demand for regular monitoring. Cost transparency: DTC services often provide upfront pricing, contrasting with the often opaque costs of traditional healthcare-ordered testing.
CPA can be taken by mouth or by injection into muscle. It has near-complete oral bioavailability, is highly and exclusively bound to albumin in terms of plasma protein binding, is metabolized in the liver by hydroxylation and conjugation, has 15β-hydroxycyproterone acetate (15β-OH-CPA) as a single major active metabolite, has a long elimination half-life of about 2 to 4 days regardless of route of administration, and is excreted in feces primarily and to a lesser extent in urine.
The racemic form has mild amphetamine-like psychostimulant effects that are diminished compared to those of amphetamine but are still present. The levorotatory enantiomer has further reduced stimulant effects, and further work, published in 1967, determined that the levorotatory enantiomer was a more potent MAOI than the dextrorotatory enantiomer. As a result, subsequent work was done with the single enantiomer L-deprenyl. In 1968, it was discovered by J. P. Johnston that monoamine oxidase exists in multiple forms. In 1971, Knoll showed that selegiline highly selectively inhibits the B-isoform of monoamine oxidase (MAO-B) and proposed that it is unlikely to cause the infamous "cheese effect" (hypertensive crisis resulting from consuming foods containing tyramine) that occurs with non-selective MAOIs. The lack of potentiation of tyramine effect by deprenyl had previously been reported in 1966 and 1968 studies, but could not be mechanistically explained until after the existence of multiple forms of MAO was discovered. Selegiline was the first selective MAO-B inhibitor to be discovered and hence is described as prototypical of these agents. Deprenyl and selegiline were initially studied as antidepressants for treatment of depression. Deprenyl was first found to be effective for depression from 1965 to 1967, while selegiline was first found to be effective for depression in 1971 and this was further corroborated in 1980.
To determine the equilibrium constant for this reaction, in which the ligand loses a proton, the pKa of the protonated ligand must be known. In practice, the ligand may be polyprotic; for example EDTA4− can accept four protons; in that case, all pKa values must be known. In addition, the metal ion is subject to hydrolysis, that is, it behaves as a weak acid, so the pK values for the hydrolysis reactions must also be known. Assessing the hazard associated with an acid or base may require a knowledge of pKa values. For example, hydrogen cyanide is a very toxic gas, because the cyanide ion inhibits the iron-containing enzyme cytochrome c oxidase. Hydrogen cyanide is a weak acid in aqueous solution with a pKa of about 9. In strongly alkaline solutions, above pH 11, say, it follows that sodium cyanide is "fully dissociated" so the hazard due to the hydrogen cyanide gas is much reduced. An acidic solution, on the other hand, is very hazardous because all the cyanide is in its acid form. Ingestion of cyanide by mouth is potentially fatal, independently of pH, because of the reaction with cytochrome c oxidase. In environmental science acid–base equilibria are important for lakes and rivers; for example, humic acids are important components of natural waters. Another example occurs in chemical oceanography: in order to quantify the solubility of iron(III) in seawater at various salinities, the pKa values for the formation of the iron(III) hydrolysis products Fe(OH)2+, Fe(OH)+2 and Fe(OH)3 were determined, along with the solubility product of iron hydroxide.
=== eHealth and mobile Health (mHealth) interventions === A new emerging area of support for disease management is through digital technology using eHealth and mobile health (mHealth) interventions. These interventions have to potential to support the development of self-management skills, or assist the healthcare team to monitor symptoms. For JIA, current studies have focused on the health issues pain, health related quality of life, physical activity and disease management. Children and adolescents have used these interventions through a range of devices including computers, laptops, personal digital assistants, multimedia-players, and wearable accelerometers synchronised to smart phone. This allows access to these interventions from home. Early usability studies have been gaining positive feedback by children and adolescents. They are familiar with this type of technology and report liking these interventions. However further research is still needed to understand their full potential in supporting children and adolescents living with complex needs.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.